When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
JNJ - I-Mab Biopharma commences registrational MM study in China
Johnson & Johnson
Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-licensed rights to the candidate from MorphoSys AG (NASDAQ:MOR) in November 2017 in China, Taiwan, Hong Kong and Macao.
More news on: MorphoSys AG, Johnson & Johnson, Sanofi, Healthcare stocks news,